Examining the link between donor telomere length and outcomes in acute leukemia patients after stem cell transplantation
Official title: The First Affiliated Hospital, Zhejiang University School of Medicine
Run by Zhejiang University · NCT06076226 · Data updated 2026-11-12
This study is trying to see if the length of telomeres in blood from stem cell donors can affect how well patients with acute leukemia do after their transplant.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 5 Years to 90 Years |
| Sex | All |
| Enrollment | 2500 (estimated) |
| Sponsor | Zhejiang University Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Status | Recruiting |
| Started | January 1, 2015 |
| Main results expected | December 1, 2025 |
| Study ends | December 1, 2026 |
| Registry record updated | October 10, 2023 |
| Trial ID | NCT06076226 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients aged 5 years and older with acute leukemia who have undergone their first allo-HSCT and achieved complete remission.
✕Probably not a fit
Patients with non-acute leukemia diagnoses or those who did not achieve full donor chimerism after transplantation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study analyzes the relationship between donor leukocyte telomere length and the prognosis of patients with acute leukemia who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT). It includes patients aged 5 years and older who achieved complete remission and full donor chimerism post-transplant. The study assesses donor blood samples for telomere length prior to granulocyte colony-stimulating factor mobilization. The research is conducted at two major hospitals in China, ensuring ethical compliance and informed consent.
Why it matters
Potential benefit: If successful, this study could provide insights into how donor characteristics influence patient outcomes, potentially leading to improved transplant strategies.
How similar studies have gone: While similar studies have explored donor characteristics in transplantation, this specific focus on telomere length in acute leukemia is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 5 years * First allo-HSCT from matched related, unrelated, or haploidentical donors * Achievement of complete remission after allo-HSCT * Donor blood sample collection before granulocyte colony-stimulating factor mobilization Exclusion Criteria * Non-acute leukemia diagnoses, including acute myeloid leukemia, acute lymphocytic leukemia, and mixed phenotype acute leukemia * Failure to achieve engraftment with full donor chimerism after allo-HSCT * Inability to extract DNA for telomere length analysis.
Where it's running
-
Clinical research ethics committee of the first affiliated hospital, college of medicine, zhejiang University
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Study coordinator: He Huang, PhD&MD
- Email: huanghe@zju.edu.cn
- Phone: +86 13605714822
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Menin inhibitors in pediatric relapsed or refractory acute leukemia
This study looks at kids with relapsed or treatment-resistant acute leukemia who have specific genetic changes and are treated with menin inhibitors to see how they fare.
-
Artistic and movement activities to help anxiety in kids with ALL
Kids aged 8–13 with acute lymphoblastic leukemia test whether a 16-session art and movement program can reduce anxiety compared with standard care.
-
Strength Training for Kids with Acute Lymphoblastic Leukemia and Lymphoblastic L lymphoma
Researchers are testing a structured strength-training program for children and teens recently diagnosed with ALL or lymphoblastic lymphoma to see if it helps with weight gain and physical function during treatment.
-
QUAIL-100 in kids and young adults after stem cell transplant with high-risk blood cancers
This study tests QUAIL-100 in pediatric and young adult patients who have high-risk acute leukemia or myelodysplastic syndrome and have already received a partially matched stem cell transplant.
-
Thiotepa-based Conditioning With Reduced Post-Transplant Cyclophosphamide for Allogeneic Stem Cell Transplant in High-Risk Blood C cancers
This phase 1 trial tests a Thiotepa, Busulfan, and Fludarabine conditioning regimen with de-escalated post-transplant cyclophosphamide to see if it can improve outcomes after allogeneic stem cell transplantation for high-risk blood cancers.
-
Menin inhibitor maintenance after allogeneic stem cell transplant
This project will try menin inhibitor maintenance to see if it helps people with acute leukemia after allogeneic stem cell transplant who have KMT2A or related gene changes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.